ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM) is a purified glycoprotein consisting of 2,332 amino acids that is synthesized by a genetically engineered Chinese hamster ovary (CHO) cell line. In culture, the CHO cell line expresses recombinant antihemophilic factor (rAHF) into the cell culture medium. The rAHF is purified from the culture medium using a series of chromatography columns. The cornerstone of the purification process is an immunoaffinity chromatography step in which a monoclonal antibody directed against Factor VIII is employed to selectively isolate the rAHF from the medium. The cell culture and purification processes used in the manufacture of ADVATE rAHF-PFM employ no additives of human or animal origin. The production process includes a dedicated, viral inactivation solvent-detergent treatment step. The rAHF synthesized by the CHO cells has the same biological effects as Antihemophilic Factor (Human) [AHF (Human)]. Structurally the recombinant protein has a
similar combination of heterogeneous heavy and light chains as found in AHF (Human).
ADVATE rAHF-PFM is indicated in hemophilia A (classical hemophilia) for the prevention and control of bleeding episodes. ADVATE rAHF-PFM is also indicated in the perioperative management of patients with hemophilia A. ADVATE rAHF-PFM can be of therapeutic value in patients with Factor VIII inhibitors not exceeding 10 Bethesda Units (BU) per mL.1, 2 However, in patients with a known or suspected inhibitor to Factor VIII, the plasma Factor VIII level should be monitored frequently and the dose of ADVATE rAHF-PFM should be adjusted accordingly.
ADVATE rAHF-PFM is not indicated for the treatment of von Willebrand's disease.
Published Studies Related to Advate (Antihemophilic Factor)
Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. [2000.06]
To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII (rFVIII) product has been developed without human-derived plasma proteins during purification and formulation and using an additional solvent/detergent viral inactivation step...
Clinical Trials Related to Advate (Antihemophilic Factor)
Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A [Completed]
The study will consist of two parts: a safety and efficacy period in which all subjects will
participate and a pharmacokinetic analysis period, in which 30 eligible subjects will
participate to compare ReFacto AF and Advate bioequivalency and safety and efficacy of
ReFacto AF in patients with Hemophilia A.
Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A [Active, not recruiting]
The purpose of this study is to determine the effect of 3 doses of ADVATE rAHF-PFM on initial
recovery (% increase [IU/dL] per IU/kg infused) and major single-infusion pharmacokinetic
parameters. The 3 doses are 15, 30, and 50 IU/kg. Prior to each infusion, subjects will not
have received treatment with a factor VIII concentrate for at least 3 days. Blood samples
will be drawn within 30 minutes pre-infusion and at 0. 25, 0. 5, 1, 3, 6, 9, 24, 28, 32 and 48
hours post-infusion. A washout period of at least 3 days, but no more than 30 days between
the last blood draw and the next infusion will be observed. During participation, subjects
will maintain their preexisting treatment regimens with ADVATE rAHF-PFM or other factor VIII
A secondary objective is to investigate the relationship between pharmacokinetic parameters
at each dose level and the levels of von Willebrand factor ristocetin cofactor activity and
von Willebrand factor antigen at baseline.
Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A [Terminated]
Most transient inhibitor formation, if any, will develop within the first 4 weeks. The study
is to further monitor whether participants with severe Hemophilia A will develop inhibitors
or antibodies at the later stage when switched from their current recombinant therapy
produced from Chinese Hamster Ovary (CHO) cell line to KogenateŽ-FS raised in a Baby Hamster
Kidney cell line.
Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings [Recruiting]
The study will be investigating safety in patients who switch to ReFacto AF from ReFacto and
other Factor VIII products.
Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A [Completed]
Reports of Suspected Advate (Antihemophilic Factor) Side Effects
Factor Viii Inhibition (33),
Device Related Infection (8),
Gingival Bleeding (4),
Condition Aggravated (4),
Movement Disorder (3), more >>
Page last updated: 2006-01-31